title: Anti-inflammatory and anticatabolic effects of short-term beta-hydroxy-beta-methylbutyrate supplementation on chronic obstructive pulmonary disease patients in intensive care unit.
abstract: Elevated inflammatory markers and muscle wasting were common in chronic obstructive pulmonary disease (COPD) patients. The purpose of this study was to investigate the effect of 7-day beta-hydroxy-beta-methylbutyrate (HMB) supplementation on inflammation, protein metabolism, and pulmonary function in COPD patients in an intensive care unit. Thirty-four COPD patients who required mechanical ventilators were randomly assigned to HMB (n=18) or control (n=16) groups. The HMB group received HMB 3 g/d for 7 days. White blood cell count, C-reactive protein, and creatinine were significantly lower, while cholesterol and total protein were significantly higher after HMB supplementation. The body weight remained unchanged in both groups. Ten subjects (55.6%) in the HMB group and 4 subjects (25.0%) in the control group had improved pulmonary function, indicated by their ventilator modes. This short-term study suggests that HMB supplementation may have anti-inflammatory and anticatabolic effect and improve pulmonary function in COPD patients in an intensive care unit setting.
authors.affiliation: Department of Dietetics, Kaohsiung Municipal United Hospital, Kaohsiung, Taiwan, ROC.
authors.forename: Lan-Chi
authors.initials: LC
authors.lastname: Hsieh
authors.forename: Shu-Ling
authors.initials: SL
authors.lastname: Chien
authors.forename: Ming-Shong
authors.initials: MS
authors.lastname: Huang
authors.forename: Hung-Fu
authors.initials: HF
authors.lastname: Tseng
authors.forename: Chen-Kang
authors.initials: CK
authors.lastname: Chang
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood; D019587:Dietary Supplements; D004734:Energy Metabolism / Q000187:drug effects* / Q000502:physiology; D005260:Female; D006801:Humans; D007362:Intensive Care Units; D007958:Leukocyte Count; D008168:Lung / Q000187:drug effects* / Q000502:physiology; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D012129:Respiratory Function Tests; D016896:Treatment Outcome; D014631:Valerates / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D014631:Valerates; C004961:beta-hydroxyisovaleric acid; D002097:C-Reactive Protein; D002784:Cholesterol; D003404:Creatinine